Beta2-Agonists

Excerpt

Beta-2 adrenergic agonists are used as a mainstay treatment for respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). They replicate the functions of catecholamines, such as epinephrine, norepinephrine, and dopamine, in producing various autonomic responses within the body. Specifically, the smooth muscle of the airway, uterus, intestine, and systemic vasculature are areas where beta-2 agonists have the most significant effect. Thus, the focus of development for this drug class has been primarily on the clinical implications related to their ability to affect the target organ systems. Over the last century, extensive research has been conducted on these drugs' bronchodilatory and anti-bronchoconstrictive properties.

The early 1900s marked the advent of epinephrine as a form of treatment in Western medicine, following its successful extraction from the adrenal gland. This became the standard treatment for patients with asthma until it was replaced in the 1940s with the introduction of isoproterenol, a nonselective beta-adrenergic receptor agonist. However, the adverse effects of isoproterenol became an issue of concern, and the search continued for a treatment with a better adverse effect profile. With the discovery of the alpha-1, alpha-2, beta-1, and beta-2 receptors in subsequent years, it became known that airway bronchodilation had a strong correlation specifically with beta-2 receptors in the lung vasculature.

Pharmacological pursuits focused on maximizing selectivity for the beta-2 receptor to reduce the incidence of adverse effects associated with the nonselective isoproterenol. These new drugs, classified as beta-2 adrenergic receptor agonists, have since become frontline treatments for bronchial asthma and COPD. Subsequent research aims to enhance efficacy, minimize adverse effects, alleviate symptoms, decrease mortality rates, and improve patient quality of life. However, since the discovery of beta-2 agonists, there have been many discussions regarding the potential long-term risks versus benefits to the overall rate of morbidity and mortality. This article aims to provide a foundational background on the mechanism of action of beta-2 agonists, their various classifications, and their associated clinical significance; also discussed are areas of concern and speculation regarding this class of medications.